What’s New in the 2026 Diabetes Care Guidelines — And What It Means for Patients

Why the 2026 ADA Standards Matter Nationwide

If you or someone in your family lives with diabetes, the American Diabetes Association’s (ADA) annual Standards of Care in Diabetes shape much of the treatment you receive.

These guidelines, published in the journal Diabetes Care, are used by clinicians, health systems, and insurers across the United States. They review randomized clinical trials, large observational studies, and other evidence, then grade recommendations by strength — from high-quality evidence (often multiple randomized trials) to expert consensus when data are more limited.

The 2026 update builds on recent years’ shifts toward earlier use of technology, more personalized medication choices, and stronger protection against heart and kidney disease — the leading causes of complications in diabetes.

Here is what changed, what the evidence shows, and what it may mean for everyday patients.

Diabetes in the U.S.: A Continuing Public Health Challenge

According to the CDC’s most recent National Diabetes Statistics Report, about 40.1 million people in the United States — roughly 12% of the population — were living with diagnosed or undiagnosed diabetes in 2023. About 29.1 million have been diagnosed, and an estimated 11 million adults may not yet know they have it.

Prediabetes is even more common. The CDC estimates more than 115 million U.S. adults have prediabetes, and most are unaware.

Why this matters: Diabetes increases the risk of heart disease, stroke, kidney failure, vision loss, nerve damage, and gum (periodontal) disease. Many of these complications are preventable with early detection, consistent monitoring, and risk-based treatment.

What Changed in 2026: Earlier and Broader Use of Continuous Glucose Monitoring

One of the clearest shifts in the 2026 Standards is stronger support for earlier and broader use of continuous glucose monitoring (CGM).

CGMs are wearable sensors that measure glucose levels throughout the day and night. Instead of relying only on fingerstick checks, patients and clinicians can see patterns, time spent in target range, and overnight trends.

What’s new:

Offering CGM at or near the time of diagnosis for people likely to benefit.
Expanded support for people using insulin — including many with type 2 diabetes, not only type 1.
Ongoing endorsement of automated insulin delivery systems for appropriate patients.

Much of the evidence behind CGM recommendations comes from randomized trials showing improved A1C levels, reduced hypoglycemia (dangerously low blood sugar), and better time-in-range for insulin users. For people with type 1 diabetes, these benefits are well established. For people with type 2 diabetes on insulin, evidence has grown over the past several years.

What this means for patients: If you are still relying only on fingersticks — especially if you use insulin — it may be worth asking your clinician whether CGM is appropriate and whether your insurance covers it.

Medication Updates: GLP-1 Drugs, SGLT2 Inhibitors, and Individualized Therapy

The 2026 Standards continue to emphasize that diabetes treatment is no longer one-size-fits-all.

For many people with type 2 diabetes, medication decisions now depend not only on A1C levels, but also on:

Heart disease risk
Kidney function
Weight considerations
Risk of low blood sugar
Cost and access

GLP-1 receptor agonists and related medications have been shown in large randomized cardiovascular outcome trials to reduce major heart events in people with type 2 diabetes and established cardiovascular disease. Many also support weight loss and improved glucose control.

SGLT2 inhibitors have demonstrated cardiovascular and kidney protection in multiple randomized trials, including in people with chronic kidney disease or heart failure.

The ADA 2026 guidance reinforces:

Using medications with proven cardiovascular benefit in patients at high heart risk.
Using medications with kidney-protective effects in patients with chronic kidney disease.
Tailoring therapy to the individual rather than escalating medications solely based on A1C.

It is important to note that not every patient qualifies for these medications. Eligibility depends on risk profile, kidney function, other conditions, and insurance coverage. Long-term safety data continue to evolve for some newer therapies.

Protecting the Heart and Kidneys: More Than Glucose Control

Managing blood sugar is only one part of diabetes care.

The 2026 Standards place continued emphasis on aggressive cardiovascular and kidney risk reduction. That includes:

Updated blood pressure targets for certain higher-risk groups.
Cholesterol management using statins when indicated.
Routine screening for kidney damage using urine albumin and estimated GFR.
Prioritizing medications with proven heart and kidney benefits when appropriate.

Large randomized trials over the past decade have consistently shown that reducing blood pressure and using certain glucose-lowering drugs lowers the risk of heart attack, stroke, and kidney failure in high-risk patients.

Practical takeaway: Ask your clinician about your A1C, blood pressure, cholesterol, and kidney numbers — and how they fit into your overall cardiovascular risk.

Expanded Screening: Mental Health and Whole-Person Care

Living with diabetes requires daily decision-making. The 2026 update strengthens recommendations for screening:

Diabetes distress
Depression and anxiety
Cognitive concerns in older adults

Evidence shows that mental health directly affects glucose control and medication adherence. Screening tools are generally brief questionnaires used during visits.

The Standards also reinforce routine screening for complications affecting:

Eyes (retinopathy exams)
Kidneys (urine and blood tests)
Nerves (neuropathy checks)
Oral health (gum disease risk)

Gum disease and diabetes have a two-way relationship: uncontrolled blood sugar increases the risk of periodontal disease, and severe gum disease can make glucose harder to manage. Regular dental care remains an important — and sometimes overlooked — part of diabetes management.

Costs, Medicare, and Insurance Realities

Technology and newer medications can improve care, but cost remains a major issue.

Medicare, under CMS policy, covers continuous glucose monitoring for many beneficiaries who meet criteria, including insulin use. However, coverage rules, documentation requirements, and copays vary. Private insurance and Medicaid policies also differ by state and plan.

GLP-1–based medications and SGLT2 inhibitors can be expensive. Many plans require prior authorization, and coverage for weight-management indications may be more limited than for diabetes treatment.

What patients can do:

Ask your clinician whether documentation supports medical necessity.
Check your formulary and prior authorization requirements.
Ask about patient assistance programs if cost is a barrier.

The ADA guidelines inform coverage decisions, but they are not mandates. Insurers may adopt recommendations at different speeds.

What Has Not Changed

Despite expanded technology and medication options:

There is still no cure for diabetes.
Nutrition, physical activity, sleep, and weight management remain foundational.
Routine monitoring and preventive care are essential.
Not every new therapy is appropriate for every person.

Some long-term safety data for newer medications and devices are still accumulating. Ongoing studies will continue to refine guidance in future updates.

What This Means for Readers

The 2026 ADA Standards signal a clear direction: diabetes care is becoming more personalized, more technology-supported, and more focused on preventing heart and kidney complications.

If you live with diabetes or prediabetes:

Know your A1C, blood pressure, cholesterol, and kidney numbers.
Ask whether CGM could help you.
Discuss whether your medications also protect your heart and kidneys.
Do not ignore mental health or dental health — both affect overall outcomes.
Have a conversation about cost and coverage before starting new therapies.

Guidelines evolve as evidence grows. The most important step is staying engaged with your care team and asking informed questions about what fits your health goals, risks, and resources.

Sources

This article is for general informational purposes only and is not medical advice. Research findings can be early, limited, or subject to change as new evidence emerges. For personal guidance, diagnosis, or treatment, consult a licensed clinician. For current outbreak or public health guidance, follow your local health department, the CDC, or another relevant public health authority.